Dan is chief medical officer of Beacon Therapeutics, an ocular gene therapy company that has completed pivotal clinical trials of its lead agent, Lara-Zova, a gene therapy for X-linked retinitis pigmentosa caused by variants in the RPGR gene. Previously, Chung was chief medical officer at SparingVision, helped Spark Therapeutics develop Luxturna and served as a researcher at the University of Pennsylvania Perelman School of Medicine and at the Children’s Hospital of Philadelphia.